20 January 2022
IntegraGen and BIOASTER have been collaborating for several years in the context of genomic and transcriptomic analyses. Driven by a desire to strengthen this relationship further, the two entities have entered into a long-term partnership agreement (Master Research Service Agreement). This agreement will facilitate and accelerate exchanges between (…) »
19 January 2022
Rendez-nous visite à Rennes lors des prochaines Assises de Génétique qui auront lieu du 1er au 4 février 2022. C’est sur le stand n°20 que nous vous accueillerons avec le plus grand des plaisirs.
Les prises de rendez-vous et inscriptions à notre atelier-déjeuner “Après l’ère du séquençage ciblé, les solutions (…) »
14 January 2022
Significant increase in services delivered by SeqOIA and the Mutualized Microbiology (P2M) platform operated on behalf of the Institut Pasteur Stability of sequencing services provided by the Evry laboratory
EVRY, FRANCE, FRIDAY 14 JANUARY 2021, 7.30 – IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), an OncoDNA group (…) »
24 December 2021
Ditsa Keren is a technology blogger and entrepreneur with a strong passion for biology, ecology and the environment. She spoke to our CEO Bernard Courtieu to hear about the latest advancements in precision medicine and the promise we bring to oncology physicians and researchers.
Discover the entire interview on (…) »
24 September 2021
OncoXPLORE, a comprehensive cancer gene panel test for the exploration of solid tumors
On the occasion of the World Cancer Research Day, OncoDNA proudly announces the launch of its latest genomic solution for cancer research, OncoXPLORE. OncoDNA has long been a strong supporter of cancer research. Through a (…) »
16 July 2021
A Powerful Workflow to Access Cancer Gene Expression Signatures
In additional to DNA sequencing, RNA sequencing can provide researchers and clinicians with additional insights into tumor tissues. The technology offers the opportunity to explore the gene expression profiles and the states of tumor cells in real time.
16 July 2021
Slight revenue growth despite the impact of the pandemic during the first half of the year. Strong increase in order intake sets the stage for an anticipated dynamic growth during the second half of the 2021.
EVRY, FRANCE, FRIDAY 16 JULY 2021, 7.30AM – IntegraGen (FR0010908723 – ALINT (…) »
25 June 2021
Founded in 1961, the Antoine Lacassagne Center is one of the 18 French Cancer Centers of the Unicancer network. It fulfills missions of care, research and teaching in oncology. The Antoine Lacassagne Center treats all types of cancer and receives more than 6,400 patients (…) »
16 June 2021
Following its acquisition by OncoDNA, IntegraGen has been given a brand new look and is ready to take on new projects in the fields of cancer and genetic diseases.
Since the successful takeover in November 2020, IntegraGen has been working hand in hand with OncoDNA (…) »
15 March 2021
Uropathogenic E.coli induces DNA damage in the bladder
As provider of the whole genome sequencing, IntegraGen is proud of sharing this new publication.
Urinary tract infections (UTIs) are caused by an uropathogenic strain of Escherichia coli that produce colibactin, a bacterial genotoxin.
In the study (…) »